Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis

Journal of the Neurological Sciences

Volumn 246, Issue 1-2, 2006, Pages 71-77

  Mei, Feng Jun ^a   Osoegawa, Manabu ^a   Ochi, Hirofumi ^a   Minohara, Motozumi ^a   Nan, Shi ^a   Murai, Hiroyuki ^a   Ishizu, Takaaki ^a   Taniwaki, Takayuki ^a   Kira, Jun ichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Interferon ; Interferon ; Interleukin 13; Interleukin 4; Multiple sclerosis; Th1; Th2

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 13; INTERLEUKIN 4;

ADULT; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL COUNT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; DRUG TREATMENT FAILURE; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; INTRACELLULAR SPACE; JAPAN; LONG TERM EXPOSURE; MALE; MEASUREMENT; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TH2 CELL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; HUMANS; INTERFERON-BETA; JAPAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; RECURRENCE; T-LYMPHOCYTES, CYTOTOXIC; TH2 CELLS; TREATMENT OUTCOME;

EID: 33744535722     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.02.008     Document Type: Article

References (21)

1. Martin R., McFarland H.F., and McFarlin D.E. Immunological aspects of demyelinating diseases. Annu Rev Immunol 10 (1992) 153-187
2. Jacobsen M., Cepok S., Quak E., Happel M., Gaber R., Ziegler A., et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 125 (2002) 538-550
3. Gay F.W., Drye T.J., Dick G.W., and Esiri M.M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 120 (1997) 1461-1483
4. Babbe H., Roers A., Waisman A., Lassmann H., Goebels N., Hohlfeld R., et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192 (2000) 393-404
5. Dayal A.S., Jensen M.A., Lledo A., and Arnason B.G.W. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 45 (1995) 2173-2177
6. Furlan R., Bergami A., Lang R., Brambilla E., Franciotta D., Martinelli V., et al. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4. J Neuroimmunol 111 (2000) 86-92
7. Byrnes A.A., McArthur J.C., and Karp C.L. Interferon-β therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol 51 (2002) 165-174
8. Franciotta D., Zardini E., Bergamaschi R., Andreoni L., and Cosi V. Interferon γ and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment. J Neurol Neurosurg Psychiatry 74 (2003) 123-126
9. Koike F., Satoh J., Miyake S., Yamamoto T., Kawai M., Kikuchi S., et al. Microarray analysis identifies interferon β-regulated genes in multiple sclerosis. J Neuroimmunol 139 (2003) 109-118
10. Šega S., Wraber B., Mesec A., Horvat A., and Ihan A. IFN-β b1a and IFN-β1b have different patterns of influence on cytokines. Clin Neurol Neurosurg 106 (2004) 255-258
11. The PRISMS Study Group, and UBC MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-la in relapsing MS. Neurology 56 (2001) 1628-1636
12. Ochi H., Mei F.-J., Osoegawa M., Minohara M., Murai H., Taniwaki T., et al. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. J Neurol Sci 222 (2004) 65-73
13. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
14. Kira J., Kanai T., Nishimura Y., Yamasaki K., Matsushita S., Kawano Y., et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 40 (1996) 569-574
15. Picker L.J., Singh M.K., Zdraveski Z., Treer J.R., Waldrop S.L., Bergstresser P.R., et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 86 (1995) 1408-1419
16. Ochi H., Osoegawa M., Wu X.-M., Minohara M., Horiuchi I., Murai H., et al. Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase. J Neurol Sci 201 (2002) 45-51
17. + T cells are correlated to MRI features of tissue destruction in MS. J Neuroimmunol 142 (2003) 141-148
18. Terabe M., Park J.M., and Berzofsky J.A. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 53 (2004) 79-85
19. Inoue Y., Konieczny B.T., Wagener M.E., McKenzie A.N., and Lakkis F.G. Failure to induce neonatal tolerance in mice that lack both IL-4 and IL-13 but not in those that lack IL-4 alone. J Immunol 167 (2001) 1125-1128
20. + T cells unresponsive to IL-12. J Infect Dis 183 (2001) 953-959
21. Ke B., Shen X.D., Zhai Y., Gao F., Busuttil R.W., Volk H.D., et al. Heme oxygenase 1 mediates the immunomodulatory and antiapoptotic effects of interleukin 13 gene therapy in vivo and in vitro. Hum Gene Ther 13 (2002) 1845-1857